Everest Organics Limited (BSE: EVERESTO.BO) Stock Competitors & Peer Comparison

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, ENTERO.NS has a market cap of 62B. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while ENTERO.NS trades at ₹1,423.60.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas ENTERO.NS's P/E ratio is 46.91. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to ENTERO.NS's ROE of +0.07%. Regarding short-term risk, EVERESTO.BO is more volatile compared to ENTERO.NS. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check ENTERO.NS's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, QMSMEDI.NS has a market cap of 2.9B. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while QMSMEDI.NS trades at ₹148.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas QMSMEDI.NS's P/E ratio is 21.23. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to QMSMEDI.NS's ROE of N/A. Regarding short-term risk, EVERESTO.BO is more volatile compared to QMSMEDI.NS. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check QMSMEDI.NS's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, ACHYUT.BO has a market cap of 1.7B. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while ACHYUT.BO trades at ₹7.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas ACHYUT.BO's P/E ratio is 700.00. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to ACHYUT.BO's ROE of +0.01%. Regarding short-term risk, EVERESTO.BO is more volatile compared to ACHYUT.BO. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check ACHYUT.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, RAMAVISION.BO has a market cap of 1.7B. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while RAMAVISION.BO trades at ₹161.00.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas RAMAVISION.BO's P/E ratio is 166.32. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to RAMAVISION.BO's ROE of +0.21%. Regarding short-term risk, EVERESTO.BO is less volatile compared to RAMAVISION.BO. This indicates lower risk in terms of short-term price fluctuations for EVERESTO.BO.Check RAMAVISION.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, BALAXI.NS has a market cap of 1.2B. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while BALAXI.NS trades at ₹22.40.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas BALAXI.NS's P/E ratio is -4.23. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to BALAXI.NS's ROE of +0.01%. Regarding short-term risk, EVERESTO.BO is more volatile compared to BALAXI.NS. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check BALAXI.NS's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, BIJHANS.BO has a market cap of 642.2M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while BIJHANS.BO trades at ₹85.62.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas BIJHANS.BO's P/E ratio is 570.80. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to BIJHANS.BO's ROE of N/A. Regarding short-term risk, EVERESTO.BO is more volatile compared to BIJHANS.BO. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check BIJHANS.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, VIVOBIOT.BO has a market cap of 428.5M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while VIVOBIOT.BO trades at ₹19.31.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas VIVOBIOT.BO's P/E ratio is -23.55. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to VIVOBIOT.BO's ROE of -0.03%. Regarding short-term risk, EVERESTO.BO is less volatile compared to VIVOBIOT.BO. This indicates lower risk in terms of short-term price fluctuations for EVERESTO.BO.Check VIVOBIOT.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, RAJNISH.BO has a market cap of 396M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while RAJNISH.BO trades at ₹0.39.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas RAJNISH.BO's P/E ratio is -6.50. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to RAJNISH.BO's ROE of -0.05%. Regarding short-term risk, EVERESTO.BO is less volatile compared to RAJNISH.BO. This indicates lower risk in terms of short-term price fluctuations for EVERESTO.BO.Check RAJNISH.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, CBPL.BO has a market cap of 376.5M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while CBPL.BO trades at ₹49.90.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas CBPL.BO's P/E ratio is 12.35. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to CBPL.BO's ROE of +0.10%. Regarding short-term risk, EVERESTO.BO is more volatile compared to CBPL.BO. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check CBPL.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, MONOPHARMA.NS has a market cap of 149.3M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while MONOPHARMA.NS trades at ₹8.45.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas MONOPHARMA.NS's P/E ratio is 4.83. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to MONOPHARMA.NS's ROE of N/A. Regarding short-term risk, EVERESTO.BO is more volatile compared to MONOPHARMA.NS. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check MONOPHARMA.NS's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, NEXUSSURGL.BO has a market cap of 106.6M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while NEXUSSURGL.BO trades at ₹19.49.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas NEXUSSURGL.BO's P/E ratio is 228.86. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to NEXUSSURGL.BO's ROE of +0.56%. Regarding short-term risk, EVERESTO.BO is less volatile compared to NEXUSSURGL.BO. This indicates lower risk in terms of short-term price fluctuations for EVERESTO.BO.Check NEXUSSURGL.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, NATURO.BO has a market cap of 51.5M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while NATURO.BO trades at ₹2.61.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas NATURO.BO's P/E ratio is -5.93. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to NATURO.BO's ROE of -0.02%. Regarding short-term risk, EVERESTO.BO is more volatile compared to NATURO.BO. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check NATURO.BO's competition here

Everest Organics Limited (BSE: EVERESTO.BO) plays a significant role within the Healthcare sector. Its performance on the BSE reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, EVERESTO.BO stands at 2.9B. In comparison, EVOQ.BO has a market cap of 42.6M. Regarding current trading prices, EVERESTO.BO is priced at ₹297.80 on the BSE, while EVOQ.BO trades at ₹1.71.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

EVERESTO.BO currently has a P/E ratio of 52.25, whereas EVOQ.BO's P/E ratio is -17.10. In terms of profitability, EVERESTO.BO's ROE is +0.07%, compared to EVOQ.BO's ROE of -0.01%. Regarding short-term risk, EVERESTO.BO is more volatile compared to EVOQ.BO. This indicates higher risk in terms of short-term price fluctuations for EVERESTO.BO.Check EVOQ.BO's competition here